BALKANPHARMA

Location:

Bulgaria

Project number:

13947

Business sector:

Manufacturing and Services

Notice type:

Private

Environmental category:

B

Approval date:

27 Mar 2001

Status:

Completed

PSD disclosed:

28 Feb 2001

Project Description

Proposed loan to support modernisation of Balkanpharma’s pharmaceutical production facilities in a plan to achieve Good Manufacturing Practice (GMP) certification.
The project would allow the company to upgrade its production facilities to Western standards, with the goal of obtaining GMP certification. The project involves construction of new facilities, modernisation of existing facilities, and environmental upgrades.
 

Transition Impact

Pharmaceutical production has traditionally been a flagship industry in Bulgaria. While privatisation in the sector has already been completed, the project will demonstrate that the industry can attract long-term corporate lending from international sources. The success of Balkanpharma will also demonstrate the competence of the workforce in a technically sophisticated sector of the economy. The project will have a strong demonstration effect and will facilitate the preparation of Bulgarian industry towards EU accession.

The Client

Balkanpharma Holding AD Bulgaria is a Bulgarian joint-stock company which owns controlling interests in three pharma-ceutical production companies in Bulgaria: Balkanpharma-Razgrad AD, Balkanpharma-Dupnitza AD, and Balkanpharma-Troyan AD.

EBRD Finance

EUR21.5 million corporate loan, with one-year grace and four-year repayment period.

Project Cost

EUR24.7million

Environmental Impact

The project has been screened B/1, requiring an environmental analysis and an environmental audit. International environmental consultants undertook environmental due diligence, which included an independent assessment of past environmental damage. An environmental specialist from the EBRD's Environmental Appraisal Unit also conducted a site visit to the three facilities in January 2001. Balkanpharma facilities are all currently in compliance with Bulgarian legislation. Furthermore, US Food and Drug Administration (FDA) regularly inspects the Razgrad facility as bulk chemicals are marketed in the United States, and no significant compliance issues have been raised during recent visits. Because of this experience of dealing with the FDA, systems, procedures and staff training in a range of safety and environmental controls are complete across all areas of the site. Since privatisation, the company has substantially upgraded its pharmaceutical manufacturing facilities which, along with the Bank's investment, will significantly improve Balkanpharma's performance against EU and World Bank environmental, health and safety standards. These upgrades are detailed in the Environmental Action Plan (EAP), which form part of the company's capital investment programme. Environmental issues form a crucial component of the international requirements for Good Manufacturing Practice (GMP) and environmental upgrades will add significantly to the company’s strategy to export products to western Europe. The implementation of the EAP and introduction of environmental, health and safety management practices will establish a strong basis for continuous improvement of environmental performance and will assist in achieving GMP certification. The company's proactive approach to environmental issues should act as a useful demonstration to other Bulgarian companies.
 

Technical Cooperation

None.

Company Contact

 

Business opportunities

For business opportunities or procurement, contact the client company.

For state-sector projects, visit EBRD Procurement: Tel: +44 20 7338 6794
Email: procurement@ebrd.com

General enquiries

EBRD project enquiries not related to procurement:
Tel: +44 20 7338 7168
Email: projectenquiries@ebrd.com

Public Information Policy (PIP)

The PIP sets out how the EBRD discloses information and consults with its stakeholders so as to promote better awareness and understanding of its strategies, policies and operations. Please visit the Public Information Policy page below to find out how to request a Public Sector Board Report.
Text of the PIP

Independent Project Accountability Mechanism (IPAM)

If efforts to address environmental, social or public disclosure concerns with the Client or the Bank are unsuccessful (e.g. through the Client’s Project-level grievance mechanism or through direct engagement with Bank management), individuals and organisations may seek to address their concerns through the EBRD’s Independent Project Accountability Mechanism (IPAM).

IPAM independently reviews Project issues that are believed to have caused (or to be likely to cause) harm. The purpose of the Mechanism is: to support dialogue between Project stakeholders to resolve environmental, social and public disclosure issues; to determine whether the Bank has complied with its Environmental and Social Policy or Project-specific provisions of its Access to Information Policy; and where applicable, to address any existing non-compliance with these policies, while preventing future non-compliance by the Bank.

Please visit the Independent Project Accountability Mechanism webpage to find out how to submit a Request for review through our confidential online form, by email, mail or telephone. IPAM is available to discuss your concerns and answer any questions you may have about the submission or handling of Requests, which follow the Project Accountability Policy and Guidance. Requestors’ identities may be kept confidential, upon request.

Share this page: